# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data Reque...
Roth MKM analyst Jason Wittes initiates coverage on Monogram Technologies (NASDAQ:MGRM) with a Buy rating and announces Pric...
Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused o...
The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review. The FDA informed the Company ...
Monogram Technologies (NASDAQ:MGRM) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate ...
Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive ReviewFDA Decisi...
New Name Reflects Continued Evolution as an AI-Driven Robotics Company with a Strong IP Position